- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:54 | Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies | 94 | GlobeNewswire (Europe) | The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo... ► Artikel lesen | |
| ARTELO BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | Artelo Biosciences GAAP EPS of -$0.89 | 2 | Seeking Alpha | ||
| Do | Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results | 822 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling... ► Artikel lesen | |
| Mi | ARTELO BIOSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.08. | Artelo Biosciences: Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma | 213 | GlobeNewswire (Europe) | Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology Initial DREAM Study Results Anticipated in Q4 2026 SOLANA BEACH, Calif.... ► Artikel lesen | |
| 22.07. | Artelo Biosciences: New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy - Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition | 3 | GlobeNewswire (USA) | ||
| 17.07. | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions | 237 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signalling... ► Artikel lesen | |
| 14.07. | Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 | 1 | GlobeNewswire (USA) | ||
| 13.07. | Artelo reports positive neuropathic pain study results for ART27.13 | 1 | Investing.com | ||
| 13.07. | Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy | 166 | GlobeNewswire (Europe) | Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building... ► Artikel lesen | |
| 01.07. | Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury | 1 | GlobeNewswire (USA) | ||
| 30.06. | Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 | 1 | GlobeNewswire (USA) | ||
| 29.06. | Artelo presents phase 1 data for FABP5 inhibitor ART26.12 | 1 | Investing.com | ||
| 29.06. | Artelo Biosciences präsentiert positive Phase-1-Daten für FABP5-Inhibitor ART26.12 | - | Investing.com Deutsch | ||
| 29.06. | Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 | 1 | GlobeNewswire (USA) | ||
| 10.06. | Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success | 1 | GlobeNewswire (USA) | ||
| 27.05. | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Artelo Biosciences GAAP EPS of $4.00 | 2 | Seeking Alpha | ||
| 14.05. | ARTELO BIOSCIENCES, INC. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,05 | -1,80 % | Moderna-Aktie: Plötzlich deutlich besser als BioNTech | Die Moderna-Aktie überrascht die Börse rund um das Wochenende mit einem neuen Höhenflug. Nachdem der Kurs des Biotech-Konzerns bereits am Freitag um +10% in die Höhe geschossen ist, setzt sich die gute... ► Artikel lesen | |
| BB BIOTECH | 57,90 | +2,84 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| QIAGEN | 37,105 | -0,50 % | Qiagen-Aktie: Jetzt auf Fünfmonatshoch - lohnt sich der Einstieg? | Qiagen-Aktien legen heute kräftig zu. An der Frankfurter Börse kletterten die Papiere des Diagnostikspezialisten um 4 Prozent nach oben und markierten damit den höchsten Stand seit fünf Monaten. Der... ► Artikel lesen | |
| MODERNA | 56,03 | +2,39 % | Pharma and Biotech Stocks in the Spotlight: Moderna, BioNxt Solutions, and Eli Lilly | ||
| AMGEN | 360,80 | +0,52 % | Amgen lays groundwork for new R&D center in Hyderabad | ||
| NOVAVAX | 6,940 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| STRYKER | 288,80 | -1,47 % | Stryker-Aktie: Startet über 352,65 US$ die nächste Rally? | Die Stryker-Aktie hat sich nach dem scharfen Rücksetzer aus dem Frühjahr deutlich erholt und notiert inzwischen wieder bei 345,81 US$. Damit rückt der entscheidende Widerstandsbereich um 352,65 US$... ► Artikel lesen | |
| BIOGEN | 181,00 | -0,17 % | Wolfe Research stuft Biogen und AbbVie hoch: Starke Pipeline und günstige Bewertung als Treiber | ||
| BIOFRONTERA | 2,350 | -2,08 % | Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation | ||
| ILLUMINA | 166,62 | +0,99 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,090 | +1,71 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,610 | -0,31 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,178 | +1,20 % | Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen | ||
| INOVIO PHARMACEUTICALS | 0,950 | +1,28 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,200 | -2,68 % | Pharma- und Biotech-Aktien im Fokus mit Moderna, BioNxt Solutions und Eli Lilly! | Viele Patente der großen Pharmariesen laufen in den kommenden Jahren aus. Wenn der Schutz weg ist, dann drohen Umsatzeinbußen durch Nachahmer-Medikamente, die sogenannten Generika. Entsprechend hoch... ► Artikel lesen |
Das Unternehmen ARTELO BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,30 % bei einem Aktienkurs von 0,756 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTELO BIOSCIENCES INC finden Sie auf Wallstreet Online.